Diamyd Medical joins international consortium in Type 1 Diabetes
Diamyd Medical will be a full voting member of the Type 1 Diabetes Consortium (T1DC) led by the US non-profit organization the Critical Path Institute (C-Path). The T1DC brings together diverse stakeholders from industry, academia and patient organizations to develop solutions to accelerate drug development for Type 1 Diabetes, including biomarker endpoints and model-informed drug development tools in close collaboration with regulatory agencies to enable easier and faster regulatory approval of new treatments.By creating a unique assembly of data from previous prevention and intervention